Key Highlights
•
Scientists have discovered three distinct genetic subtypes of multiple sclerosis (MS) that predict how quickly a patient’s disability will worsen and whether they will respond to treatment. This breakthrough could allow doctors to use a patient’s genetic profile to choose the most effective therapy and predict long-term outcomes, moving beyond the current ‘one-size-fits-all’ approach.
Source →
•
A new study suggests that a common treatment for Alzheimer’s disease, the anti-amyloid antibody lecanemab, does not have a unique advantage in targeting a specific form of amyloid protein compared to other similar drugs. This finding raises new questions about why lecanemab causes fewer dangerous brain swelling side effects, challenging current assumptions about how these drugs work.
Source →
•
For people living with moderate to advanced Dementia with Lewy Bodies, the frequency of cognitive fluctuations—times when thinking and alertness suddenly change—is strongly linked to a worse quality of life and a higher burden of neuropsychiatric symptoms like anxiety and hallucinations. This highlights that managing these confusing mental changes is just as important as treating other core symptoms of the disease.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
